迷幻药物（包括LSD、MDMA和魔法蘑菇）在精神卫生治疗中展现出了潜力，但同时伴随着显著的风险。澳大利亚在这一领域占据独特地位：作为1970年代停止迷幻药物研究最晚的国家之一，它也成为2024年最早重启此类物质医学用途合法使用的国家之一1。
关于治疗效果，研究报告存在明显差异。一名参加澳大利亚1970年代临床试验的患者称该治疗"深具价值"和"令人惊叹"，声称其"稳定了我的生活，现在我不害怕任何事"1。2013年挪威研究则表明迷幻药物使用与更高的心理健康问题发病率无关1。与此同时，MDMA被发现具有"深刻的亲社交作用"，包括"欣快感、幸福感、与他人的连接和同理心"1。
然而，不利影响也同样令人担忧。美国麻省总医院最近的研究发现迷幻药物可能引发强烈的恐惧、情绪困顿、偏执、困惑、自杀念头、精神病和躁狂发作1。2024年一次蘑菇使用中，一名女性死亡，其他参与者经历了瘫痪、失语和呼吸困难1。研究人员因此强调，迷幻药物是"工具而非治疗手段"，应与心理治疗结合使用1。
Psychedelic substances including LSD, MDMA, and psilocybin mushrooms are being reconsidered as potential treatments for mental health conditions, according to a review of journalist Rich Haridy's new book Trip Reports 1. Australia occupies a unique position in this emerging field, having been among the last countries to halt psychedelic research in the 1970s and among the first to legalize their medical use in 2024 1.
The therapeutic potential is evident in documented cases. One Australian trial participant from the 1970s described the treatment as "deeply valuable" and "marvellous," stating that it "stabilised my life. I'm not frightened of anything now" 1. MDMA has been found to produce "profound pro-social effects," including "euphoria, happiness, connection to others, empathy" 1. A 2013 Norwegian study indicated that psychedelic use was "not associated with a higher rate of mental health problems" 1.
However, the safety profile remains contested and concerning. A 2024 incident involving psilocybin mushrooms resulted in one woman's death, while other participants experienced paralysis, loss of speech, and difficulty breathing 1. Research from Massachusetts General Hospital in the United States has identified potential severe adverse effects, including "intense fear, emotional distress, paranoia, confusion," as well as suicidal ideation, psychosis, and manic episodes 1. Researchers emphasize that these substances function as "tools not treatments" and should be used in conjunction with psychological therapy rather than as standalone interventions 1.
评论
还没有评论，欢迎留下第一条。